MEDX — medmix AG Income Statement
0.000.00%
Last trade - 00:00
- CH₣620.70m
- CH₣848.80m
- CH₣486.60m
- 63
- 27
- 22
- 28
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 421 | 351 | 457 | 477 | 487 |
Cost of Revenue | |||||
Gross Profit | 162 | 121 | 181 | 175 | 158 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 383 | 333 | 397 | 458 | 471 |
Operating Profit | 38.2 | 18.1 | 59.9 | 19.6 | 16 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 30.9 | 10.5 | 51.3 | 12.2 | 2.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | 25.2 | 9.7 | 44 | 11.6 | 0.7 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 25.2 | 9.7 | 44 | 11.6 | 0.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 25.2 | 9.6 | 44 | 11.6 | 0.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.09 | 0.375 | 1.09 | 0.88 | 0.24 |
Dividends per Share |